Clinical Trial Update: Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for CF101 investigating safety and efficacy in Keratoconjunctivitis Sicca has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconjunctivitis Sicca

Drugs mentioned

• CF101 (piclidenoson)

Snippet

Sponsor: Can-Fite BioPharma | Conditions: Keratoconjunctivitis Sicca | Phase 2 | Status: COMPLETED | Results posted: 2011-08-12